Treats major depressive disorder (MDD). ANDA 206975, held by Heritage Pharma. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 206975 (Bupropion Hydrochloride), held by Heritage Pharma, was first approved by FDA on Aug 19, 2016, with 7 approved supplements and 0 published complete response letters.
Bupropion hydrochloride tablets are an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2016 | Original application | Approved | None posted |
| Bupropion Hydrochloride75MG · tablet;oral | Bupropion Hydrochloride | Rx |
| Bupropion Hydrochloride100MG · tablet;oral | Bupropion Hydrochloride | Rx |
| Nov 6, 2025 | Supplement 35Labeling · Standard review | Approved | None posted |
| May 7, 2024 | Supplement 30Labeling · Standard review | Approved | None posted |
| Feb 7, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Feb 7, 2023 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 11, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 11, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 11, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 19, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters